Jeffrey G. Spragens - Dec 7, 2022 Form 4 Insider Report for SAB Biotherapeutics, Inc. (SABS)

Role
Director
Signature
/s/ Jeffrey G. Spragens
Stock symbol
SABS
Transactions as of
Dec 7, 2022
Transactions value $
$99,999
Form type
4
Date filed
12/9/2022, 08:02 AM
Previous filing
May 23, 2022
Next filing
Mar 2, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SABS Common Stock Award $100K +83K +26.6% $1.21 395K Dec 7, 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SABS Warrant (Common Stock) Award +83K 83K Dec 7, 2022 Common Stock 83K $1.08 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On December 6, 2022, the Registrant entered into a securities purchase agreement with Mr. Jeffrey Spragens in connection with a private placement conducted by the Registrant, pursuant to which Mr. Spragens purchased (i) an aggregate of 82,987 shares (the "Shares") of the Registrant's common stock, par value $0.0001 per share and (ii) warrants to purchase up to an aggregate of 82,987 shares of common stock at an exercise price of $1.08, at a combined purchase price of $1.205 per share and accompanying warrant. The warrants are exercisable six months from the date of issuance and expire five years from the date of issuance.